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Introduction: In clinical situations, vascular calcification tends to progress and is difficult to completely arrest or
reverse. Calciphylaxis, a severe complication of end-stage renal disease, is a specific form of vascular calcification.
Control studies have provided evidence that monotherapy with sodium thiosulfate or cinacalcet delays the progression
of vascular calcification. Successful treatment of calciphylaxis with sodium thiosulfate or cinacalcet has also been
reported. We report a case demonstrating the regression of vascular calcification following an acute episode of
necrotic skin lesions suspected to be calciphylaxis. During the successful multimodal treatment, sodium thiosulfate
and cinacalcet were sequentially administered in addition to surgical debridement and percutaneous transluminal
angioplasty.
Case presentation: We describe the case of a 71-year-old Asian woman on hemodialysis who presented with
suspected calciphylaxis lesions in her lower left leg. Plain radiographs revealed diffuse calcified vessel changes in her
lower extremities. During the initial wound treatment with a course of intravenous sodium thiosulfate, our patient’s
predialysis serum levels of total calcium markedly increased, yielding no calciphylaxis improvement. The necrotic
wounds began healing only after surgical debridement. A percutaneous transluminal angioplasty was performed to
dilate a 70% stenosis in her left posterior tibial artery. Our patient was then treated with cinacalcet, resulting in
improved control of her calcium, phosphate and parathyroid hormone serum levels. The lesions completely healed
after six months of multimodal treatment. Repeated plain radiographs in the following two years revealed gradual
vascular calcification regression in her lower extremities.
Conclusion: In addition to the favorable outcome of our patient’s wounds, radiology was used to document the
regression of calcification in the large and small arteries of her lower limbs. However, it is difficult to determine the
precise mechanism of the multimodal treatment that caused the vascular calcification regression and wound healing.
The clinical course suggested that the surgical treatment and percutaneous transluminal angioplasty substantially
contributed to healing her wounds. Cinacalcet and sodium thiosulfate may have played distinct roles in the regression
of her vascular calcification. A well-controlled study or large case series are required to assess the additive effects of
these agents when treating vascular calcification.
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In addition to accelerated atherosclerosis, patients with
end-stage renal disease are subject to diffuse medial calcifi-
cation in the blood vessels; this is associated with increased
cardiovascular mortality. Calciphylaxis, also known as cal-
cific uremic arteriolopathy, is a specific and devastating
form of vascular calcification (VC) and represents a severe
complication of end-stage renal disease. Calciphylaxis is* Correspondence: scy1@ms4.hinet.net
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reproduction in any medium, provided the orcharacterized by calcification in the media of the small- to
medium-sized blood vessels of the dermis and subcutane-
ous fat, with or without endovascular fibrosis, causing
thrombotic occlusion and resultant ischemic ulcers and
tissue necrosis. Caucasian ethnicity, female sex, obesity,
hyperphosphatemia, hypercalcemia and the use of warfarin
are known risk factors. Early recognition and prompt treat-
ment are vital, and clinical suspicion is a critical feature of
the diagnosis. Research has indicated that positive patho-
logic findings, such as arteriolar calcification, subintimal
fibroplasia, thrombosis and ischemic cutaneous necrosis,. This is an open access article distributed under the terms of the Creative
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dures are subject to sampling errors and can initiate ulcer
formation and propagation [1]. A bone scan can reveal
abnormal subcutaneous uptake in clinically apparent areas
of disease, but this is likely only true regarding non-
ulcerating lesions in viable tissue or deep and widespread
lesions. Plain radiographs of the relevant soft tissues can
demonstrate calcification among small blood vessels and
play a role in diagnostics [1-3]. Treating calciphylaxis is
challenging and multidisciplinary because of the lack of an
optimal medical therapy; it involves strictly controlling the
mineral metabolism, avoiding calcium and vitamin D
analogues, and conducting diligent wound care, including
scrupulous surgical management. Certain studies have
reported successful treatment of calciphylaxis with sodium
thiosulfate (STS) or cinacalcet [4]. In clinical situations,
established VC tends to progress and is difficult to com-
pletely arrest or reverse. Recent studies have focused on
how STS or cinacalcet affect the evolution of VC, but
further research is necessary to elucidate the optimal use
of these agents.
Case presentation
A 71-year-old Asian woman with end-stage renal disease,
who had undergone eight years of hemodialysis, presented
with spontaneous painful plaque in her left lower calf with
the surrounding skin exhibiting violaceous discoloration.
Our patient had hypertension, dyslipidemia and osteopor-
osis but no history of diabetes, connective tissue diseases
or chronic viral hepatitis. Because of recurrent thrombosis
at the vascular access point for hemodialysis, she had
received six months of warfarin therapy that ended five
months prior to developing the calf lesion. Our patient
had a long history of secondary hyperparathyroidism and
had been treated with intravenous calcitriol for manyFigure 1 Photographs of calciphylaxis lesions on the left calf. (A) Six w
eschars. (B) Before surgical debridement, the lesions showed necrotic chan
six months of multimodal treatment.years. Because of frequent episodes of hypercalcemia and
hyperphosphatemia, intravenous calcitriol had to be dis-
continued so often as to result in inadequate control of
her secondary hyperparathyroidism. Despite replacing the
calcium-containing phosphate binders with sevelamer and
shifting calcitriol to paricalcitol, her metabolic problems
with calcium and phosphorous showed little improve-
ment. In the previous four years, her serum levels of
intact parathyroid hormone typically ranged from 350
to 800pg/mL, her calcium levels were around 9.5 to
10.6mg/dL and her phosphate serum levels were approxi-
mately 5.0 to 7.4mg/dL.
In the ensuing weeks, her lesions became ulcerative
and eschars covered the wound surfaces (Figure 1A).
Plain radiographs indicated marked calcification in the ves-
sels of her lower extremities (Figures 2A, 3A and 4A). A
network of calcified vessels as small as 0.5mm in diameter
was located in the retromalleolar region of her left leg, near
the skin lesions (Figure 2A). Calciphylaxis was suspected
and intravenous STS was administered three times a week
after each session of hemodialysis. The maintenance dose
was 12g, equivalent to 15.4g per 1.73m2 of body surface
area. Her predialysis serum calcium levels demonstrated a
notable change from 10.4mg/dL to as high as 11.8mg/dL
after initiating STS therapy. The dialysate calcium concen-
tration was subsequently decreased from 2.5 to 2.0mEq/L
stepwise and dialysis frequency was increased from three
to four times per week. Treatment with paricalcitol (4μg,
three times per week) was also stopped. As a result, her
predialysis calcium levels decreased to 10.8mg/dL during
the remaining STS treatment course (Figure 5). Neverthe-
less, necrotic changes continued as the ulcers expanded.
STS was discontinued after five weeks of treatment. The
laboratory data showed that her predialysis calcium levels
declined to less than 10mg/dL in one week. Despite aeeks after onset, the lesions became ulcerative, exhibiting surface
ges as the ulcers expanded. (C) The lesions healed completely after
Figure 2 Plain radiographs of the left lower leg and ankle. (A) Six weeks after the onset of skin lesions, substantial calcifications were visible
in the posterior tibial artery and a network of small vessels in the retromalleolar region, near the skin lesions. (B) After 11 months, the vessel
calcification in the retromalleolar region was almost completely resolved and calcification in the posterior tibial artery showed apparent
regression. (C) After a subsequent 11 months of cinacalcet treatment, the posterior tibial artery demonstrated further calcification regression.
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gent wound care and pain control, the lesions worsened
and eventually required surgical debridement (Figure 1B).
Three months after the onset of skin lesions, our
patient was hospitalized and scrupulous debridement was
performed to excide the gangrenous tissue. The pathology
of the gangrenous tissue revealed necrotic debris and
inflammatory cellular exudates. The wound culture exhi-
bited Acinetobacter baumannii growth, so intravenous
amoxicillin-clavulanate was administered based on a sen-
sitivity test. Because of the active infection of the skin
lesions and fear of deepening or expanding the wound, no
tissue biopsy was performed. Computed tomography angi-
ography revealed diffuse vascular wall calcifications andFigure 3 Plain radiographs of the right knee. (A) Before specific treatm
(B) After 11 months, the small vessel calcification showed substantial regreatherosclerotic changes of the low abdominal aorta and
bilateral iliac arteries, and marked calcification of the large
and small arteries of both lower extremities (Figure 6A,B).
Conventional angiography showed a 70% stenosis in her
left posterior tibial artery (Figure 6C) and a percutaneous
transluminal angioplasty was performed for dilation. Our
patient was discharged after one month of hospitali-
zation, showing improvement of the lesion after aggressive
wound care. Cinacalcet was concomitantly administered
to treat the hyperparathyroidism and hypercalcemia. Her
predialysis calcium level declined from 9.8 to 8.2mg/dL in
two weeks. We adjusted the cinacalcet dosage between
25 and 50mg/day and the dialysate calcium concentration be-
tween 2.5 and 3.0mEq/L to avoid symptomatic hypocalcemia.ent, the joint space exhibited obvious small vessel calcification.
ssion.
Figure 4 Plain radiographs of the right thigh. (A) A calcified subcutaneous vessel (arrows) presented before specific treatment. (B) The calcified
small vessel was completely absent after 11 months.
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two months after discharge (Figure 1C). Repeated plain
radiographs in the following two years revealed gradual
VC regression in both lower extremities (Figures 2B,C, 3B
and 4B). The network of small vessel calcifications in the
retromalleolar region almost completely resolved. During
a two-year follow-up period, during which cinacalcet
treatment continued, her serum calcium levels typically
remained at approximately 8.4 to 9.4mg/dL, her phos-
phate at 4.1 to 6.4mg/dL, and her intact parathyroid
hormone at 250 to 480pg/mL. No vitamin D analogues orFigure 5 Serum calcium, phosphate, and intact parathyroid hormone
surgical debridement). The sodium thiosulfate treatment began in week
levels markedly increased compared with the levels before and after treatm
9 because hypercalcemia persisted. The dialysate calcium concentration wa
(presented as Ca 2.5, Ca 2.2 and Ca 2.0). Sevelamer was used throughout th
i-PTH, intact parathyroid hormone.calcium-containing phosphate binders were used. Further-
more, no skin lesions recurred.
Discussion
Calciphylaxis lesions typically affect the lower limbs, but
can appear on the abdomen, buttocks or breasts. Accord-
ing to a clinical study, the most common site of initial
involvement is located 2 to 5cm above the Achilles tendon
[1]. Clinical manifestations of calciphylaxis include viol-
aceous skin lesions and subcutaneous nodules or plaques
that can develop into painful ulcers, exhibiting eschars orlevels in the first 14 weeks of the disease (the period before
7 and ended in week 12. During this period, the predialysis calcium
ent. Paricalcitol (4μg, three times per week) was discontinued in week
s decreased from 2.5 to 2.2mEq/L, and then to 2.0mEq/L, stepwise
e course of treatment. STS, sodium thiosulfate; Pi, serum phosphate;
Figure 6 Diffuse calcifications and atherosclerotic changes of the vessels. Computed tomography angiographies without enhancement
showed (A) marked vascular wall calcifications and atherosclerotic changes of bilateral common iliac arteries and (B) marked calcification of
the large and small arteries of both lower legs. (C) Conventional angiography showed a 70% stenosis in left posterior tibial artery, indicating
atherosclerotic change of the vessel.
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calciphylaxis in our patient based on her characteristic
clinical presentation, contributory history, radiographic
findings and exclusion of other mimicking diseases, and
treated her accordingly. This case was limited by the lack
of a tissue diagnosis; nevertheless, it is noteworthy for
various reasons. First, we used plain radiographs as a con-
venient and useful method to assess the evolution of VC.
Second, after using multimodal therapeutic efforts, includ-
ing STS and cinacalcet, her VC gradually regressed. Third,
intravenous STS yielded elevated serum calcium levels;
however, this phenomenon and its clinical significance
require confirmation.
A simple imaging method that is widely available,
cost-effective and delivers only a small dose of radiation
is required to screen for cardiovascular calcification.
Mammography was postulated as superior to plain radiog-
raphy and computed tomography for revealing arteriolar
calcification in areas of calciphylaxis [5]; however, its util-
ity must be validated. In one study, cardiovascular cal-
cification screenings conducted using plain radiographs
showed a strong correlation with computed tomography
measurements [6]. The presence of arterial calcifications
on plain radiographs has been classified into intimal
calcification, exhibiting a patchy distribution, and medial
calcification, exhibiting a linear or railroad-track arrange-
ment. In a study of seven patients with calciphylaxis, the
plain radiographs of all patients demonstrated linear calci-
fication of the small vessels [2]. Plain radiographs of ourpatient yielded the same pattern of linear calcification over
both lower limbs, including a network of small vessel cal-
cifications in the diseased area of calciphylaxis. A recent
study reported that a net-like calcification pattern demon-
strated a strong association with calciphylaxis (odds ratio,
9.4) and a specificity of nearly 90% [3].
STS is used to treat calciphylaxis because it acts as an
antioxidant in reversing endothelial dysfunction and
binds with calcium deposits in tissues, forming a highly
soluble calcium thiosulfate salt. However, in the largest
case series that used a consecutive design to reduce
reporting bias, only two of six STS-treated patients were
complete responders [7]. Although STS treatment did
not ameliorate the wound in our patient, we cannot
exclude its possible contribution to the regression of
VC. A study of patients on hemodialysis showed that
STS could decrease the rate of VC progression [8]. An-
other clinical study proved that STS delayed the progres-
sion of coronary artery calcification; however, in the
treatment group, the bone mineral density of the hip
substantially declined [9]. We discontinued using STS
early in the treatment of our patient not for a lack of
clinical improvement, but because of concerns regarding
the unanticipated serum calcium surge and its possible
clinical effects. If the excess calcium was primarily derived
from bone tissue, the pre-existing osteoporosis of our
patient would be exacerbated.
No previous report has described elevated serum calcium
levels when STS was used in clinical settings. In a case of
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STS to treat calciphylaxis increased the calcium concentra-
tion in peritoneal effluent, leading to the removal of excess
calcium [10]. Given the powerful effects of mobilizing
tissue calcium, an increase in the serum calcium level
seems reasonable when STS is administered intravenously.
After a careful literature analysis, we determined that
researchers typically made therapeutic adjustments to
minimize calcium loading and optimize calcium removal
when STS was administered; these adjustments might
conceal the calcium-elevating effects of STS. Our clinical
findings are supported by a controlled animal study in
which calcium concentrations rose from the baseline con-
centration 45 minutes after administering STS [11].
Cinacalcet is a calcimimetic that acts on the calcium-
sensing receptor of parathyroid cells, reducing parathyroid
hormone and attenuating hypercalcemia. In addition to
cases of healing calciphylaxis, it has been reported that
cinacalcet treatment reduces vascular and pulmonary
calcification [12]. In a study of uremic rats treated with
cinacalcet, the bone formation rate was normalized and
VC development was inhibited [13]. The concomitant
reduction of VC in these animals might have resulted
from the intensified mineralization of the osteoid limiting
the availability of calcium and phosphate for deposition in
the vascular wall. Because calcium-sensing receptors can
be found on vascular smooth muscle cells, cinacalcet is
believed to directly affect VC inhibition. In humans, a
controlled study of patients on hemodialysis showed that
cinacalcet inhibits the progress of coronary artery cal-
cification [14]. In the ADVANCE study, patients who
received cinacalcet and low-dose vitamin D demonstrated
less VC progression than did patients who were adminis-
tered vitamin D analogues alone [15]. To the best of our
knowledge, no reports have explored how combined STS
and cinacalcet therapy affects VC evolution.
It is difficult to determine the precise mechanism of
multimodal treatment responsible for the regression of
VC and wound healing. According to the clinical course,
the necrotic wounds of our patient began healing only
after surgical debridement. The percutaneous translumi-
nal angioplasty procedure used to treat the stenosis in her
left posterior tibial artery might also have contributed to
the healing of the lesions. However, VC regression oc-
curred not only in her lower left leg but also in her right
thigh and knee, where no percutaneous transluminal
angioplasty was performed; thus, this procedure fails to
explain the effects of VC regression. Although the VC
regression could have been the natural course of the
disease, the tendency of VC to progress casts doubt on
this possibility. Among the therapeutic modalities used to
treat our patient, no single treatment could have con-
tributed more to the VC regression than did cinacalcet
and STS; various clinical studies have demonstrated theinhibitory effects of STS and cinacalcet on the progression
of VC. During the two-year course of the gradual VC
regression exhibited by our patient after wound healing,
cinacalcet was the only specific treatment that could inter-
fere with vessel calcification. However, based on accumu-
lated clinical reports, VC regression is not common after
cinacalcet treatment. To explain the rare and astonishing
regression of VC in our patient, we suspect that the
preceding STS treatment dissolved a portion of calcium
precipitate in the vascular wall, changing the composition
or structure of the calcification to facilitate the inhibitory
effect of cinacalcet on calcification. Nevertheless, addi-
tional evidence is required to support this hypothesis.
Conclusions
Plain radiography could be a convenient and useful
method to assess the evolution of VC. Because VC is
highly associated with cardiovascular mortality, we require
an effective method to not only delay but reverse the pro-
gression of this highly pathogenic illness. In addition to a
favorable wound outcome, our patient exhibited regressed
calcifications of the large and small arteries in her lower
limbs. According to the clinical course, the surgical treat-
ment and percutaneous transluminal angioplasty proced-
ure substantially contributed to wound healing. Regarding
the regression of VC, treatment with cinacalcet and STS
might have played distinct roles. A well-controlled study
or large case series should be conducted to assess the
additive effects of these agents in treating VC.
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